Though the Gila monster may have led the news, the real story was that with the approval of BYETTA, adult patients with type 2 diabetes T2D and prescribers had a new class of diabetes treatment — called glucagon-like peptide-1 receptor agonists, or GLP-1 RAs. The GLP-1 RA class was a new therapeutic option that worked differently from other diabetes medications available at that time.
Everyone was excited about the approval, because they knew BYETTA offered another critical treatment option that could help a large number of adults with type 2 diabetes manage the condition. Exenatide is the synthetic version of a protein called exendin-4, which comes from the saliva of the Gila monster.
Ralph DeFronzo was an early investigator and adopter of exenatide. Exenatide-based products are now marketed in more than 80 countries worldwide, and it is estimated that more than 2 million people have used exenatide products since the launch of BYETTA.
Over the past 10 years, the GLP-1 receptor agonist class has grown to include five marketed products in the U.
Diabetes is projected to affect more than million people by To help address the treatment needs of people with diabetes, AstraZeneca will continue to push the boundaries of science in an effort to create life-changing medicines. BYETTA is an injectable prescription medicine that may improve blood sugar glucose control in adults with type 2 diabetes, when used with diet and exercise.
BYETTA should not be used in people with type 1 diabetes or people with diabetic ketoacidosis a condition caused by very high blood sugar. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www. Food and Drug Administration FDA in as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. The most common side effects with BYDUREON may include nausea, diarrhea, headache, vomiting, constipation, itching at the injection site, a small bump nodule at the injection site, and indigestion.
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements, as taking them with BYDUREON may affect how each medicine works.
Tell your healthcare provider if you are taking other diabetes medicines, including insulin or sulfonylureas. Tell your healthcare provider if you are pregnant or plan to become pregnant. Talk to your healthcare provider first if you are breastfeeding or plan to breastfeed. BYDUREON is an injectable prescription medicine that may improve blood sugar glucose in adults with type 2 diabetes mellitus, and should be used along with diet and exercise.
You have selected a link that will take you to a site maintained by a third party who is solely responsible for its contents. AstraZeneca provides this link as a service to website visitors. AstraZeneca is not responsible for the privacy policy of any third party websites. We encourage you to read the privacy policy of every website you visit. Important notice for users You are about to access AstraZeneca historic archive material. Any reference in these archives to AstraZeneca products or their uses may not reflect current medical knowledge and should not be used as a source of information on the present product label, efficacy data or safety data.
Please refer to your approved national product label SmPC for current product information. I have read this warning and will not be using any of the contained product information for clinical purposes. Cookie Policy This website uses cookies to help us give you the best experience when you visit.
By using this website you consent to our use of these cookies. HbA1c is a measure of average blood sugar over three months. Both treatment groups achieved a reduction in weight by the end of the study, with an average loss of 2. There were no major hypoglycaemic events in either treatment arm.
An agonist is a molecule, such as a drug or a hormone, which binds to a receptor of a cell and triggers a response by that cell. A glucagon-like peptide-1 GLP-1 receptor agonist binds to and activates the GLP-1 receptor, which exhibits multiple anti-hyperglycaemic actions. Diabetes is estimated to affect The prevalence of diabetes is projected to reach more than million people worldwide by Type 2 diabetes accounts for approximately percent of all cases of diagnosed diabetes.
Type 2 diabetes is a chronic disease characterised by pathophysiologic defects leading to elevated glucose levels. Over time, this sustained hyperglycaemia contributes to further progression of the disease.
Significant unmet needs still exist, as many patients remain inadequately controlled on their current glucose-lowering regimen. AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases.
AstraZeneca operates in over countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www. You have selected a link that will take you to a site maintained by a third party who is solely responsible for its contents. AstraZeneca provides this link as a service to website visitors.
0コメント